title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board - Climb Bio  ( NASDAQ:CLYM ) ",20241111T120000,https://www.benzinga.com/pressreleases/24/11/g41875065/climb-bio-appoints-douglas-e-williams-ph-d-as-chair-of-the-board,PFE,0.055881,Neutral,-0.043982
"Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board",20241111T120000,https://www.globenewswire.com/news-release/2024/11/11/2978194/0/en/Climb-Bio-Appoints-Douglas-E-Williams-Ph-D-as-Chair-of-the-Board.html,PFE,0.033468,Neutral,-0.042717
Pfizer's  ( PFE )  Ulcerative Colitis Pill Velsipity Gets EU Nod,20240220T120900,https://www.zacks.com/stock/news/2228287/pfizers-pfe-ulcerative-colitis-pill-velsipity-gets-eu-nod,PFE,0.354741,Somewhat-Bullish,0.245922
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,20230515T093200,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,PFE,0.017394,Neutral,0.112745
"The Zacks Analyst Blog Highlights Lilly, Merck, Roche, Pfizer and Moderna",20220620T092400,https://www.zacks.com/stock/news/1940866/the-zacks-analyst-blog-highlights-lilly-merck-roche-pfizer-and-moderna,PFE,0.334425,Neutral,-0.080136
"Pharma Stock Roundup: FDA Panel Nod for PFE, MRNA Young Kids' COVID Jabs & More",20220617T123700,https://www.zacks.com/stock/news/1940269/pharma-stock-roundup-fda-panel-nod-for-pfe-mrna-young-kids-covid-jabs-more,PFE,0.443239,Neutral,-0.118991
"The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK",20220616T140943,https://www.benzinga.com/general/biotech/22/06/27737919/the-daily-biotech-pulse-roches-alzheimers-drug-fails-advisors-back-pfizer-moderna-shots-for-young,PFE,0.098719,Neutral,-0.002903
"The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill",20220318T115038,https://www.benzinga.com/general/biotech/22/03/26197749/the-daily-biotech-pulse-moderna-files-for-2nd-covid-booster-shot-authorization-lexicon-secures-de,PFE,0.135576,Neutral,0.003182
"The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug",20220708T121902,https://www.benzinga.com/general/biotech/22/07/27998206/the-daily-biotech-pulse-pfizer-inks-pact-with-africa-for-covid-19-pills-emergent-bio-ridgeback-to,PFE,0.126985,Neutral,0.010481
103 Biggest Movers From Yesterday,20220511T102237,https://www.benzinga.com/news/22/05/27130447/103-biggest-movers-from-yesterday,PFE,0.042685,Neutral,0.003708
DNA Tech Co. Launches MRNA Platform and Files Two Patents,20230830T155527,https://www.investorideas.com/news/2023/biotech/08302Applied-DNA-Sciences.asp,PFE,0.031446,Neutral,0.144016
Applied DNA Sciences  ( NASDAQ:APDN )  Coverage Initiated by Analysts at StockNews.com,20230708T050842,https://www.defenseworld.net/2023/07/08/applied-dna-sciences-nasdaqapdn-coverage-initiated-by-analysts-at-stocknews-com.html,PFE,0.085936,Neutral,0.086494
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,PFE,0.013173,Neutral,0.026023
3 Monkeypox Stocks That Soared Last Week,20220523T091300,https://www.fool.com/investing/2022/05/23/3-monkeypox-stocks-that-soared-last-week/,PFE,0.05333,Somewhat-Bullish,0.24866
"The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More",20220516T133825,https://www.benzinga.com/general/biotech/22/05/27217168/the-week-ahead-in-biotech-may-16-21-gene-cell-therapy-conference-presentations-tapering-earnings-,PFE,0.122362,Neutral,0.006818
"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More",20220414T133544,https://www.benzinga.com/general/biotech/22/04/26630399/the-daily-biotech-pulse-pfizer-biontech-covid-19-booster-data-in-kids-regenerons-covid-19-therapy,PFE,0.125635,Neutral,0.01172
"Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA",20240313T120000,https://www.globenewswire.com/news-release/2024/03/13/2845349/0/en/Pyxis-Oncology-Expands-Board-of-Directors-with-Appointment-of-Santhosh-Palani-Ph-D-CFA.html,PFE,0.0428,Neutral,0.019547
"Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer - Dianthus Therapeutics  ( NASDAQ:DNTH ) ",20231129T210500,https://www.benzinga.com/pressreleases/23/11/g36011541/dianthus-therapeutics-enhances-leadership-team-with-appointment-of-jeffrey-stavenhagen-ph-d-as-chi,PFE,0.032691,Neutral,-0.053857
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst - Pyxis Oncology  ( NASDAQ:PYXS ) ,20230905T164314,https://www.benzinga.com/general/biotech/23/09/34244004/pyxis-oncology-m-a-spotlight-signals-potential-growth-amidst-competitive-adc-landscape-analyst,PFE,0.405651,Bullish,0.524373
Pyxis Oncology Successfully Completes Acquisition of Apexigen - Pyxis Oncology  ( NASDAQ:PYXS ) ,20230823T123500,https://www.benzinga.com/pressreleases/23/08/g34002489/pyxis-oncology-successfully-completes-acquisition-of-apexigen,PFE,0.029472,Somewhat-Bullish,0.198825
Pyxis Oncology Successfully Completes Acquisition of Apexigen,20230823T123500,https://www.globenewswire.com/news-release/2023/08/23/2730427/0/en/Pyxis-Oncology-Successfully-Completes-Acquisition-of-Apexigen.html,PFE,0.030524,Somewhat-Bullish,0.186808
CancerVAX CEO Ryan Davies Discusses Biotech Entrepreneurship with Pyxis Oncology CEO Dr. Lara Sullivan,20230710T070100,https://www.benzinga.com/pressreleases/23/07/g33159728/cancervax-ceo-ryan-davies-discusses-biotech-entrepreneurship-with-pyxis-oncology-ceo-dr-lara-sulli,PFE,0.328819,Neutral,0.118708
Pyxis  ( PYXS )  Up on Advancing Cancer Therapy Candidates,20230531T133900,https://www.zacks.com/stock/news/2101934/pyxis-pyxs-up-on-advancing-cancer-therapy-candidates,PFE,0.258351,Somewhat-Bullish,0.204503
"Apexigen  ( APGN )  to Get Acquired by Pyxis Oncology, Stock Up",20230525T192500,https://www.zacks.com/stock/news/2099939/apexigen-apgn-to-get-acquired-by-pyxis-oncology-stock-up,PFE,0.084127,Neutral,0.03958
Small SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M - Pyxis Oncology  ( NASDAQ:PYXS ) ,20230524T182848,https://www.benzinga.com/general/biotech/23/05/32554799/small-spac-biotech-apexigen-to-be-acquired-pyxis-oncology-for-16m,PFE,0.371523,Somewhat-Bullish,0.254431
"Pyxis Oncology to Acquire Apexigen - Pyxis Oncology  ( NASDAQ:PYXS ) , Apexigen  ( NASDAQ:APGN ) ",20230524T104500,https://www.benzinga.com/pressreleases/23/05/g32547139/pyxis-oncology-to-acquire-apexigen,PFE,0.0367,Neutral,0.140027
Pyxis Oncology to Acquire Apexigen,20230524T104500,https://www.globenewswire.com/news-release/2023/05/24/2675054/0/en/Pyxis-Oncology-to-Acquire-Apexigen.html,PFE,0.030216,Neutral,0.127603
"3 Top Penny Stocks To Watch As GSIT, OMH Stock Explode",20230515T170303,https://pennystocks.com/featured/2023/05/15/3-top-penny-stocks-to-watch-gsit-omh-stock-explode/,PFE,0.116536,Neutral,0.066961
"$5M Bet On Pyxis Oncology? Check Out These 4 Penny Stocks Insiders Are Buying - Bird Glb  ( NYSE:BRDS ) , Champions Oncology  ( NASDAQ:CSBR ) ",20230322T112113,https://www.benzinga.com/trading-ideas/long-ideas/23/03/31453546/5m-bet-on-pyxis-oncology-check-out-these-4-penny-stocks-insiders-are-buying,PFE,0.096283,Neutral,0.13807
"Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors",20230316T113000,https://www.globenewswire.com/news-release/2023/03/16/2628535/0/en/Pyxis-Oncology-Announces-Dosing-of-First-Subject-in-Phase-1-Trial-of-PYX-201-a-Novel-ADC-for-Solid-Tumors.html,PFE,0.06515,Somewhat-Bullish,0.160302
Pyxis Oncology Announces FDA Clearance of Two IND Applications,20221201T114500,https://www.globenewswire.com/news-release/2022/12/01/2565733/0/en/Pyxis-Oncology-Announces-FDA-Clearance-of-Two-IND-Applications.html,PFE,0.031654,Neutral,0.092079
Pyxis Oncology Announces Leadership Changes,20220413T103500,https://www.globenewswire.com/news-release/2022/04/13/2421745/0/en/Pyxis-Oncology-Announces-Leadership-Changes.html,PFE,0.03368,Bullish,0.855864
